Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in
patients with myelofibrosis.
This study investigates the following:
- The safety and tolerability of IMG-7289
- The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only)
- The pharmacodynamic effect of IMG-7289
Phase
Phase 2
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme
Enrollment Eligibility
Inclusion Criteria:
- >18 years
- Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for
myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT
- High or intermediate-2 risk disease, as defined per protocol
Exclusion Criteria:
- Receiving other treatments for the condition (with exceptions and time limits)
- Major surgery in last 4 weeks, minor surgery in the last 2 weeks
- History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of
Screening
- History of splenectomy
- Current use of prohibited medications
- A concurrent second active and nonstable malignancy
- Known HIV infection or active Hepatitis B or Hepatitis C virus infection
- Other hematologic/biochemistry requirements, as per protocol
- Use of investigational agent within last 14 days
- Pregnant or lactating females